/
SPRB
$41.88+$0.57 (+1.36%)live
Held by
1
portfolio on TandT
Bookmarked by
0
users
Avg position size
8.4%
of holders' portfolios
13F filers
0
institutions
Market cap
$115.6M
3M shares
52-week range
$7.26 – $240.00
15% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Change$-670.69
Spruce Biosciences, Inc. Common Stock
Spruce Biosciences Inc is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with unmet medical needs. The company develops biologics and small-molecule product candidates aimed at addressing diseases with unmet medical needs and limited or no approved therapies. Its product candidate, TA-ERT for the treatment of Mucopolysaccharidosis Type IIIB (MPS IIIB), is a fusion protein comprised of recombinant human alpha-N-acetylglucosaminidase (rhNAGLU) intended as an enzyme replacement therapy for patients who lack rhNAGLU enzyme activity. TA-ERT is designed to restore rhNAGLU enzyme activity in the central nervous system following intracerebroventricular injection and promote clearance of heparan sulfate in the brain.
www.sprucebiosciences.com- Employees
- 8
- IPO / List date
- Oct 9, 2020
- HQ
- SOUTH SAN FRANCISCO, CA
Held by traders on TradeandTell
| Trader / Portfolio | Conviction |
|---|---|
| July PortfolioShkreli | Mild8% |
Super investors & insiders
Institutions holding (13F)
No tracked institution reports a position in SPRB as of their last filing.
Insider activity (SEC Form 4)
Stock splits
| Execution date | Ratio |
|---|---|
| 2025-08-07 | 1-for-75reverse |
Recent trades on TradeandTell
- 7/10/2026in July Portfolio →
